Atrial Natriuretic Peptide (126-150) (rat) CAS NO.90052-57-6

The mechanism of action involves binding to and activation of the natriuretic peptide receptor A (NPR-A), a transmembrane guanylyl cyclase-coupled receptor expressed in vascular tissues, kidneys, and other target organs. Receptor engagement stimulates intracellular guanylyl cyclase activity, leading to increased production of cyclic GMP (cGMP) and activation of downstream signaling pathways including cGMP-dependent protein kinases. This signaling cascade mediates vasodilation, promotes natriuresis and diuresis by increasing renal sodium excretion, inhibits renin and aldosterone secretion, and reduces vascular smooth muscle cell proliferation. The peptide's biological activity is dependent on its native conformation maintained by the intramolecular disulfide bond, which is essential for proper receptor binding and activation.

This rat ANP (126-150) peptide is indicated for research use only in preclinical studies investigating natriuretic peptide biology, cardiovascular regulation, renal function, and related physiological processes in rat models. It serves as a specific ligand for NPR-A receptor binding assays, functional cGMP accumulation assays, and in vitro studies of vascular relaxation and renal sodium transport. The product is also used in animal experiments to study the physiological effects of ANP on blood pressure regulation, fluid and electrolyte balance, and cardiovascular function in rat-based research systems. It is particularly valuable for research on hypertension, heart failure, and renal disorders where ANP signaling may be implicated. The product is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.

As a research reagent, Atrial Natriuretic Peptide (126-150) (rat) does not have established clinical efficacy for therapeutic use in human patients. This synthetic peptide has not undergone clinical development or received regulatory approval for any medical indication. While ANP and related natriuretic peptides have been investigated in preclinical studies and some clinical trials for cardiovascular conditions, this specific rat-derived research-grade product remains an investigational tool used primarily for basic science research in rodent models. It has no proven clinical efficacy or safety profile for human use and is intended solely for laboratory research applications in appropriate scientific settings.